{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:39:59Z","timestamp":1773034799626,"version":"3.50.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":4212,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of nutrition, health and aging"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s12603-012-0057-5","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T00:27:37Z","timestamp":1337560057000},"page":"557-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?"],"prefix":"10.1016","volume":"16","author":[{"given":"A.","family":"Gurevich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Guller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.N.","family":"Berner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s12603-012-0057-5_bib1","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia","volume":"19","author":"Schneider","year":"2005","journal-title":"JAMA"},{"key":"10.1007\/s12603-012-0057-5_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2008.09.017","article-title":"Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile?","volume":"59","author":"Trifiro","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1007\/s12603-012-0057-5_bib3","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1532-5415.1990.tb02407.x","article-title":"A metaanalysis of controlled trials of neuroleptic treatment in dementia","volume":"38","author":"Schneider","year":"1990","journal-title":"J Am Geriatr Soc"},{"key":"10.1007\/s12603-012-0057-5_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/10673220500433247","article-title":"Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature","volume":"13","author":"Jeste","year":"2005","journal-title":"Harv Rev Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: Meta-analysis of randomized, placebo-controlled trials","volume":"14","author":"Schneider","year":"2006","journal-title":"Am J Geriatric Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1517\/14740338.2010.506711","article-title":"Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality","volume":"10","author":"Ballard","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1007\/s12603-012-0057-5_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1345\/aph.17215","article-title":"Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy","volume":"33","author":"Markowitz","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1007\/s12603-012-0057-5_bib8","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2165\/00002512-200623120-00002","article-title":"Adverse effects of atypical antipsychotics in the elderly: a review","volume":"23","author":"Gareri","year":"2006","journal-title":"Drugs Aging"},{"key":"10.1007\/s12603-012-0057-5_bib9","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1503\/cmaj.1041064","article-title":"J, Waraich P. Modern antipsychotic agents: A brief overview","volume":"72","author":"Gardner","year":"2005","journal-title":"Can Med Assoc J"},{"key":"10.1007\/s12603-012-0057-5_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1532-5415.2005.00566.x","article-title":"A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia","volume":"54","author":"Carson","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1007\/s12603-012-0057-5_bib12","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1212\/WNL.53.5.946","article-title":"A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia","volume":"53","author":"De Deyn","year":"1999","journal-title":"Neurology"},{"key":"10.1007\/s12603-012-0057-5_bib13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4088\/JCP.v64n0205","article-title":"A randomized placebo controlled trial of risperidone for the treatment of aggression, agitation, and psychosis in dementia","volume":"64","author":"Brodaty","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib14","doi-asserted-by":"crossref","unstructured":"Lonergan E, Luxenberg J, Colford JM, Birks J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002;(2):CD002852.","DOI":"10.1002\/14651858.CD003945"},{"key":"10.1007\/s12603-012-0057-5_bib15","first-page":"165","article-title":"Impact of antipsychotics on geriatric patients: efficacy, dosing, and compliance","volume":"2","author":"Maguire","year":"2000","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib16","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS563>3.0.CO;2-0","article-title":"Tardive dyskinesias in the elderly","volume":"16","author":"Fabbrini","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib17","first-page":"15","article-title":"Movement disorders associated with neuroleptic treatment","volume":"62","author":"Wirshing","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/mds.20823","article-title":"Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?","volume":"21","author":"Tarsy","year":"2006","journal-title":"Mov Disord"},{"key":"10.1007\/s12603-012-0057-5_bib19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/nedt.2006.2.2.235","article-title":"Neuroleptic malignant syndrome induced by atypical neuroleptics and responsive to lorazepam","volume":"2","author":"Yacoub","year":"2006","journal-title":"Neuropsychiatr Dis and Treat"},{"key":"10.1007\/s12603-012-0057-5_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: a randomized, double blind trial","volume":"60","author":"Katz","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1192\/apt.8.1.49","article-title":"Use of atypical antipsychotic drugs in old age psychiatry","volume":"8","author":"Bouman","year":"2002","journal-title":"Adv Psychiatr Treat"},{"key":"10.1007\/s12603-012-0057-5_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/gerona\/60.5.622","article-title":"Silver Network Home Care Study Group. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study","volume":"60","author":"Landi","year":"2005","journal-title":"J Gerontol Biol Sci Med Sci"},{"key":"10.1007\/s12603-012-0057-5_bib23","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1532-5415.2005.53403.x","article-title":"Atypical antipsychotic medications and risk of falls in residents of aged care facilities","volume":"53","author":"HienIe","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"10.1007\/s12603-012-0057-5_bib24","first-page":"2335","article-title":"Use of atypical antipsychotic drugs in patients with dementia","volume":"67","author":"Motsinger","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1007\/s12603-012-0057-5_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/10401230490453293","article-title":"Atypical antipsychotic induced weight gain: pathophysiology and management","volume":"16","author":"Ananth","year":"2004","journal-title":"Ann Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib26","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/archinte.1994.00420100093012","article-title":"Clinical assessment of extrapyramidal signs in nursing home patients given antipsychotic medication","volume":"154","author":"Avorn","year":"1994","journal-title":"Arch Intern Med"},{"key":"10.1007\/s12603-012-0057-5_bib27","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0022-3956(03)00018-9","article-title":"Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients","volume":"37","author":"Zimmermann","year":"2003","journal-title":"J Psychiatr Res"},{"key":"10.1007\/s12603-012-0057-5_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1464-5491.2004.01199.x","article-title":"Schizophrenia, the metabolic syndrome and diabetes","volume":"21","author":"Holt","year":"2004","journal-title":"Diabet Med"},{"key":"10.1007\/s12603-012-0057-5_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/14746514040040050301","article-title":"Newer antipsychotic agents, carbohydrate metabolism and cardiovascular risk","volume":"4","author":"Akhtar","year":"2004","journal-title":"Brit J Diabetes Vasc Dis"},{"key":"10.1007\/s12603-012-0057-5_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.jcp.0000085403.08426.f4","article-title":"Antipsychoticinduced weight gain: bipolar disorders and leptin","volume":"23","author":"McIntyre","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1007\/s12603-012-0057-5_bib31","first-page":"15","article-title":"Hyperglycemia and antipsychotic medications","volume":"62","author":"Haupt","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib32","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1210\/jcem.87.6.8599","article-title":"Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo","volume":"87","author":"Sowell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1007\/s12603-012-0057-5_bib33","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib34","first-page":"27","article-title":"Dyslipidemia and atypical antipsychotic drugs","volume":"65","author":"Casey","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib35","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The IDF Epidemiology Task Force Consensus Group. The metabolic syndrome \u2014 a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"key":"10.1007\/s12603-012-0057-5_bib36","first-page":"8","article-title":"Metabolic changes associated with antipsychotic use","volume":"6","author":"Lieberman","year":"2004","journal-title":"Prim Care Companion Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/pn.38.9.0001a","article-title":"FDA to require diabetes warning on antipsychotics","volume":"38","author":"Rosack","year":"2003","journal-title":"Psychiatr News"},{"key":"10.1007\/s12603-012-0057-5_bib38","unstructured":"Show 28: warning about hyperglycemia and atypical antipsychotic drugs [webcast]. http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/psn\/transcript.cfm?show=28. FDA Safety News. June, 2004."},{"key":"10.1007\/s12603-012-0057-5_bib39","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.bjc.6603259","article-title":"Cancer risk among users of neuroleptic medication: a population-based cohort study","volume":"95","author":"Dalton","year":"2006","journal-title":"Brit J Cancer"},{"key":"10.1007\/s12603-012-0057-5_bib40","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/archpsyc.59.12.1147","article-title":"Dopamine antagonists and the development of breast cancer","volume":"59","author":"Wang","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib41","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1001\/archinte.165.22.2677","article-title":"Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1007\/s12603-012-0057-5_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/j.1875-9114.1996.tb02929.x","article-title":"Novel versus conventional antipsychotic drugs","volume":"16","author":"Love","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1007\/s12603-012-0057-5_bib43","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(00)02066-3","article-title":"Association of venous thromboembolism and clozapine","volume":"355","author":"Hagg","year":"2000","journal-title":"Lancet"},{"key":"10.1007\/s12603-012-0057-5_bib44","first-page":"20","article-title":"Managing anticholinergic side effects","volume":"6","author":"Lieberman","year":"2004","journal-title":"Prim Care J Clin Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib45","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2165\/00002512-200118010-00004","article-title":"Antipsychotic medications and the elderly: effects on cognition and implications for use","volume":"18","author":"Byerly","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1007\/s12603-012-0057-5_bib46","unstructured":"Summary of clinical trial data on cerebrovascular adverse events (CVAEs) in randomized clinical trials of risperidone conducted in patients with dementia. London, UK. Medicines and Healthcare Products Regulatory Agency, 2004."},{"key":"10.1007\/s12603-012-0057-5_bib47","doi-asserted-by":"crossref","unstructured":"Douglas IJ. Exposure to antipsychotics and risk of stroke: self controlled case series study. Brit Med J 2008;1227\u20131232.","DOI":"10.1136\/bmj.a1227"},{"key":"10.1007\/s12603-012-0057-5_bib48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0269881107080792","article-title":"Risk of stroke with typical and atypical antipsychotics: a retrospective cohort study including unexposed subject","volume":"22","author":"Sacchetti","year":"2008","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s12603-012-0057-5_bib49","doi-asserted-by":"crossref","unstructured":"Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischemic stroke: population based retrospective cohort study. BMJ, 2005 doi:10.1136\/bmj.38330.470486.8F (Epub 2005 January 24).","DOI":"10.1136\/bmj.38330.470486.8F"},{"key":"10.1007\/s12603-012-0057-5_bib50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotics and the risk of sudden cardiac death","volume":"360","author":"Ray","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1007\/s12603-012-0057-5_bib51","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1056\/NEJMe0809417","article-title":"Antipsychotic agents and sudden cardiac death \u2014 how should we manage the risk?","volume":"360","author":"Schneeweiss","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1007\/s12603-012-0057-5_bib52","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/archinte.165.6.696","article-title":"Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest","volume":"165","author":"Liperoti","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1007\/s12603-012-0057-5_bib53","unstructured":"FDA-US. Food and Drug Administration: 2009 Public Health Advisories: Deaths with antipsychotics in elderly patients with behavioral disturbances. Available at: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PublicHealthAdvisories\/ucm053171.htm"},{"key":"10.1007\/s12603-012-0057-5_bib54","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1176\/appi.ajp.2007.06101710","article-title":"Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications","volume":"164","author":"Kales","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1007\/s12603-012-0057-5_bib55","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7326\/0003-4819-146-11-200706050-00006","article-title":"Antipsychotic drug use and mortality in older adults with dementia","volume":"146","author":"Gill","year":"2007","journal-title":"Ann Inter Med"},{"key":"10.1007\/s12603-012-0057-5_bib56","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1503\/cmaj.061250","article-title":"Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients","volume":"176","author":"Schneeweiss","year":"2007","journal-title":"Can Med Assoc J"},{"key":"10.1007\/s12603-012-0057-5_bib57","first-page":"E411","article-title":"Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes","volume":"183","author":"Huybrechts","year":"2011","journal-title":"Can Med Assoc J"},{"key":"10.1007\/s12603-012-0057-5_bib11","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/gps.504","article-title":"A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients","volume":"16","author":"Chan","year":"2001","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["The Journal of nutrition, health and aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12603-012-0057-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12603-012-0057-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1279770723015191?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1279770723015191?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12603-012-0057-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:56:58Z","timestamp":1761137818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1279770723015191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1279770723015191"],"URL":"https:\/\/doi.org\/10.1007\/s12603-012-0057-5","relation":{},"ISSN":["1279-7707"],"issn-type":[{"value":"1279-7707","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are atypical antipsychotics safer than typical antipsychotics for treating behavioral and psychological symptoms of dementia?","name":"articletitle","label":"Article Title"},{"value":"The Journal of nutrition, health and aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12603-012-0057-5","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2012 SERDI Publisher.","name":"copyright","label":"Copyright"}]}}